– BOSTON, Aug. 10, 2023 /PRNewswire/ — BMI Korea Co., LTD. (“BMI Korea”), a leading Korean biotech company specializing in biologics development, introduces its novel recombinant hyaluronidase, BMI-2004, and shares Phase 1 clinical trial results at the 15th Annual Bioprocessing Summit being held in Boston (August 14-17th, 2023) (Link to…Read More
BMI2004 A Recombinant Hyaluronidase Advancing Subcutaneous Drug Delivery Phase 1 Clinical Trial Results to Be Presented at the 15th Annual Bioprocessing Summit in Boston
